In November the MHRA also reported on a small increased risk of aortic aneurysm and dissection with systemic and inhaled fluoroquinolones. It issued advice for prescribing in high-risk patients including those with a history of blockages or aneurysms of the aorta (or other blood vessels), high blood pressure, genetic disorders that involve blood vessel changes and the elderly.